Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis

References

• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and TherapyOsteoporosis prevention, diagnosis, and therapyJAMA2001285678579511176917
   PubMed Web of Science ®Google Scholar
• CostaAGBilezikianJPLewieckiEMUpdate on romosozumab: a humanized monoclonal antibody to sclerostinExpert Opin Biol Ther201414569770724665957
   PubMed Web of Science ®Google Scholar
• International Osteoporosis Foundation [homepage on the Internet]Osteoporosis facts and statistics. International Osteoporosis Foundation Bone Health Available from: http://www.iofbonehealth.org/facts-statisticsAccessed February 11, 2015
   Google Scholar
• BurgeRDawson-HughesBSolomonDHWongJBKingATostesonAIncidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025J Bone Miner Res200722346547517144789
   PubMed Web of Science ®Google Scholar
• Kanis JA on behalf of the World Health Organization Scientific GroupAssessment of osteoporosis at the primary healthcare level Technical ReportWorld Health Organization Collaborating Centre for Metabolic Bone Diseases, University of SheffieldUK2007 Available from: http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdfAccessed February 11, 2015
   Google Scholar
• WadeSWStraderCFitzpatrickLAAnthonyMSO’MalleyCDEstimating prevalence of osteoporosis: Examples from industrialized countriesArch Osteoporos20149118224847682
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation [homepage on the Internet]What women need to know Available from: http://nof.org/articles/235Accessed February 11, 2015
   Google Scholar
• JohnellOKanisJAAn estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporos Int200617121726173316983459
   PubMed Web of Science ®Google Scholar
• RachnerTDKhoslaSHofbauerLCOsteoporosis: Now and the futureLancet201137797731276128721450337
   PubMed Web of Science ®Google Scholar
• MartinTJBone biology and anabolic therapies for bone: Current status and future prospectsJ Bone Metab201421182024707463
   PubMedGoogle Scholar
• TellaSHGallagherJCBiological agents in management of osteoporosisEur J Clin Pharmacol201470111291130125204309
   PubMed Web of Science ®Google Scholar
• BernabeiRMartoneAMOrtolaniELandiFMarzettiEScreening, diagnosis and treatment of osteoporosis: A brief reviewClin Cases Miner Bone Metab201411320120725568654
   PubMedGoogle Scholar
• AugustineMHorwitzMJParathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosisCurr Osteoporos Rep201311440040624078470
   PubMed Web of Science ®Google Scholar
• HoeppnerLHSecretoFJWestendorfJJWnt signaling as a therapeutic target for bone diseasesExpert Opin Ther Targets200913448549619335070
   PubMed Web of Science ®Google Scholar
• VeverkaVHenryAJSlocombePMCharacterization of the structural features and interactions of sclerostin: Molecular insight into a key regulator of Wnt-mediated bone formationJ Biol Chem200928416108901090019208630
   PubMed Web of Science ®Google Scholar
• BurgersTAWilliamsBORegulation of Wnt/beta-catenin signaling within and from osteocytesBone201354224424923470835
   PubMed Web of Science ®Google Scholar
• BaronRKneisselMWNT signaling in bone homeostasis and disease: From human mutations to treatmentsNat Med201319217919223389618
   PubMed Web of Science ®Google Scholar
• BaronRRawadiGTargeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeletonEndocrinology200714862635264317395698
   PubMed Web of Science ®Google Scholar
• BaronRRawadiGWnt signaling and the regulation of bone massCurr Osteoporos Rep200752738017521509
   PubMedGoogle Scholar
• AiMHeegerSBartelsCFSchellingDKOsteoporosis-Pseudoglioma Collaborative GroupClinical and molecular findings in osteoporosis-pseudoglioma syndromeAm J Hum Genet200577574175316252235
   PubMed Web of Science ®Google Scholar
• KedlayaRVeeraSHoranDJSclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndromeSci Transl Med20135211211ra158
   Web of Science ®Google Scholar
• KeuppKBeleggiaFKayseriliHMutations in WNT1 cause different forms of bone fragilityAm J Hum Genet201392456557423499309
   PubMed Web of Science ®Google Scholar
• van BezooijenRLSvenssonJPEeftingDWnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formationJ Bone Miner Res2007221192817032150
   PubMed Web of Science ®Google Scholar
• van DintherMZhangJWeidauerSEAnti-sclerostin antibody inhibits internalization of sclerostin and sclerostin-mediated antagonism of Wnt/LRP6 signalingPLoS One201384e6229523638027
   PubMed Web of Science ®Google Scholar
• PooleKEvan BezooijenRLLoveridgeNSclerostin is a delayed secreted product of osteocytes that inhibits bone formationFASEB J200519131842184416123173
   PubMed Web of Science ®Google Scholar
• AtkinsGJRowePSLimHPSclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanismJ Bone Miner Res20112671425143621312267
   PubMed Web of Science ®Google Scholar
• BalemansWEbelingMPatelNIncreased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)Hum Mol Genet200110553754311181578
   PubMed Web of Science ®Google Scholar
• Van HulWBalemansWVan HulEVan Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21Am J Hum Genet19986223913999463328
   PubMed Web of Science ®Google Scholar
• van LieropAHHamdyNAvan EgmondMEBakkerEDikkersFGPapapoulosSEVan Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriersJ Bone Miner Res201328484885423074140
   PubMed Web of Science ®Google Scholar
• BrunkowMEGardnerJCVan NessJBone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing proteinAm J Hum Genet200168357758911179006
   PubMed Web of Science ®Google Scholar
• Staehling-HamptonKProllSPaeperBWA 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch populationAm J Med Genet2002110214415212116252
   PubMed Web of Science ®Google Scholar
• BalemansWPatelNEbelingMIdentification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem diseaseJ Med Genet2002392919711836356
   PubMed Web of Science ®Google Scholar
• WergedalJEVeskovicKHellanMPatients with van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normalJ Clin Endocrinol Metab200388125778578314671168
   PubMed Web of Science ®Google Scholar
• van LieropAHHamdyNAHamersmaHPatients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnoverJ Bone Miner Res201126122804281121786318
   PubMed Web of Science ®Google Scholar
• GardnerJCvan BezooijenRLMervisBBone mineral density in sclerosteosis; affected individuals and gene carriersJ Clin Endocrinol Metab200590126392639516189254
   PubMed Web of Science ®Google Scholar
• CostaAGBilezikianJPSclerostin: Therapeutic horizons based upon its actionsCurr Osteoporos Rep2012101647222234741
   PubMed Web of Science ®Google Scholar
• LiXOminskyMSNiuQTTargeted deletion of the sclerostin gene in mice results in increased bone formation and bone strengthJ Bone Miner Res200823686086918269310
   PubMed Web of Science ®Google Scholar
• NiziolekPJFarmerTLCuiYTurnerCHWarmanMLRoblingAGHigh-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypesBone20114951010101921855668
   PubMed Web of Science ®Google Scholar
• LinCJiangXDaiZSclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signalingJ Bone Miner Res200924101651166119419300
   PubMed Web of Science ®Google Scholar
• WinklerDGSutherlandMKGeogheganJCOsteocyte control of bone formation via sclerostin, a novel BMP antagonistEMBO J200322236267627614633986
   PubMed Web of Science ®Google Scholar
• TuXRheeYCondonKWSOST downregulation and local Wnt signaling are required for the osteogenic response to mechanical loadingBone201250120921722075208
   PubMed Web of Science ®Google Scholar
• LiXOminskyMSWarmingtonKSSclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosisJ Bone Miner Res200924457858819049336
   PubMed Web of Science ®Google Scholar
• OminskyMSNiuQTLiCLiXKeHZTissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibodyJ Bone Miner Res20142961424143024967455
   PubMed Web of Science ®Google Scholar
• StolinaMDwyerDNiuQTTemporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized ratsBone20146730531325093263
   PubMed Web of Science ®Google Scholar
• LiXNiuQTWarmingtonKSProgressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibodyEndocrinology2014155124785479725259718
   PubMed Web of Science ®Google Scholar
• LiXOminskyMSWarmingtonKSIncreased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized ratsEndocrinology201115293312332221733832
   PubMed Web of Science ®Google Scholar
• LiXWarmingtonKSNiuQTInhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male ratsJ Bone Miner Res201025122647265620641040
   PubMed Web of Science ®Google Scholar
• OminskyMSLiCLiXInhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bonesJ Bone Miner Res20112651012102121542004
   PubMed Web of Science ®Google Scholar
• YaoQNiJHouYDingLZhangLJiangHExpression of sclerostin scFv and the effect of sclerostin scFv on healing of osteoporotic femur fracture in ratsCell Biochem Biophys201469222923524254971
   PubMed Web of Science ®Google Scholar
• AlaeeFVirkMSTangHEvaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect modelJ Orthop Res201432219720324600701
   PubMed Web of Science ®Google Scholar
• VirkMSAlaeeFTangHOminskyMSKeHZLiebermanJRSystemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat modelJ Bone Joint Surg Am201395869470123595067
   PubMed Web of Science ®Google Scholar
• AgholmeFIsakssonHLiXKeHZAspenbergPAnti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in ratsActa Orthop201182562863222103277
   PubMed Web of Science ®Google Scholar
• TianXSetterbergRBLiXPasztyCKeHZJeeWSTreatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female ratsBone201047352953320561907
   PubMed Web of Science ®Google Scholar
• RossRDEdwardsLHAcerboASBone matrix quality after sclerostin antibody treatmentJ Bone Miner Res20142971597160724470143
   PubMed Web of Science ®Google Scholar
• SpatzJMEllmanRCloutierAMSclerostin antibody inhibits skeletal deterioration due to reduced mechanical loadingJ Bone Miner Res201328486587423109229
   PubMed Web of Science ®Google Scholar
• CuiLChengHSongCTime-dependent effects of sclerostin antibody on a mouse fracture healing modelJ Musculoskelet Neuronal Interact201313217818423728104
   PubMed Web of Science ®Google Scholar
• OminskyMSVlasserosFJoletteJTwo doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strengthJ Bone Miner Res201025594895920200929
   PubMed Web of Science ®Google Scholar
• PadhiDJangGStouchBFangLPosvarESingle-dose, placebocontrolled, randomized study of AMG 785, a sclerostin monoclonal antibodyJ Bone Miner Res2011261192620593411
   PubMed Web of Science ®Google Scholar
• McClungMRGrauerABoonenSRomosozumab in postmenopausal women with low bone mineral densityN Engl J Med2014370541242024382002
   PubMed Web of Science ®Google Scholar
• BeckerCBSclerostin inhibition for osteoporosis – a new approachN Engl J Med2014370547647724382003
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [homepage on the Internet]RomosozumabClinicalTrials.gov A service of the US National Institutes of Health Available from: http://clinicaltrials.gov/ct2/results?term=romosozumab&Search=SearchAccessed February 11, 2015
   Google Scholar
• McColmJHuLWomackTTangCCChiangAYSingle- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal womenJ Bone Miner Res201429493594323996473
   PubMed Web of Science ®Google Scholar
• ReckerRBensonCMatsumotoTA randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in post-menopausal women with low bone mineral densityJ Bone Miner Res201530221622425196993
   PubMed Web of Science ®Google Scholar
• CiprianiCIraniDBilezikianJPSafety of osteoanabolic therapy: A decade of experienceJ Bone Miner Res201227122419242823165426
   PubMed Web of Science ®Google Scholar
• AndrewsEBGilsenanAWMidkiffKThe US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 yearsJ Bone Miner Res201227122429243722991313
   PubMed Web of Science ®Google Scholar
• BalemansWVan Den EndeJFreire Paes-AlvesALocalization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21Am J Hum Genet19996461661166910330353
   PubMed Web of Science ®Google Scholar